# A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

> **NCT05536141** · PHASE1 · RECRUITING · sponsor: **Arcus Biosciences, Inc.** · enrollment: 362 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Solid Tumors

## Interventions

- **DRUG:** casdatifan
- **DRUG:** Cabozantinib
- **DRUG:** Zimberelimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT05536141
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 362 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536141, "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05536141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*